#57 - 🩸 Your pump just got new sensors

Hey readers! If you have ever felt boxed in by having to pick one sensor for one pump, this week's news is worth your attention. The theme running through nearly every announcement: device makers are quietly dismantling the walls between pumps and CGMs, so the pieces of your loop are starting to mix and match. Let's get into who is talking to whom.

The headline this week is real interoperability, not marketing gloss. Three separate launches expanded which sensors can drive which automated insulin delivery (AID) systems, and that flexibility is the point.

MiniMed Expands European Diabetes Portfolio With Launch Of Instinct Sensor Systems puts an Abbott-developed sensor into the MiniMed world for the first time, rolling out the MiniMed 780G with the Instinct sensor and the MiniMed Go with the Instinct Go sensor across Europe starting this month. - Diabetescurehub.com

What makes this notable is that MiniMed cites a randomized crossover study in Diabetes Technology & Therapeutics showing nearly identical glycemic outcomes on the 780G whether it ran on the Simplera Sync sensor or the Instinct sensor, backed by a real-world analysis of more than 20,000 U.S. users. In other words, the choice of sensor is becoming a preference decision rather than a performance tradeoff.

One detail worth flagging for MDI users: the MiniMed Go platform folds InPen dose tracking and real-time CGM data into a single app, which is a sensible move for the many people who inject rather than pump.

Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets brings the same story from another vendor: as of July 1, the t:slim X2 with Control-IQ+ now works with Abbott's FreeStyle Libre 3 Plus in the UK, Switzerland, Sweden, Finland, and Italy, with Belgium, the Netherlands, and Germany expected during 2026. - BusinessWire via myMotherLode

The Libre 3 Plus can be worn up to 15 days and sends readings to the pump every minute, while Control-IQ+ adjusts insulin every five minutes based on predicted values. Tandem's chief medical officer Jordan Pinsker put the strategy plainly:

Insulet launches Omnipod 5, Discover in Spain rounds out the trio. Announced today, the tubeless Omnipod 5 and the Omnipod Discover data platform arrived in Spain, making it Insulet's 26th country for Omnipod and the 20th for Omnipod 5. - StockTitan (PODD)

In Spain it is indicated for people aged two and older with type 1 diabetes and, tellingly, is compatible with both the Abbott FreeStyle Libre 2 Plus and the Dexcom G7. The system adjusts insulin every five minutes, and Insulet says it is working with health authorities and autonomous communities on progressive, equitable access. The recurring pattern here is clear: whether it is MiniMed, Tandem, or Insulet, the loop is becoming modular, and Abbott and Dexcom sensors are showing up across competing pumps.

Beyond the pairings, two fresh pump designs took concrete steps toward patients, both aimed at people who have historically stuck with injections.

Modular Medical Delivers Insulin to First Patients on Pivot Tubeless Insulin Patch Pump reported on June 30 that the first patients completed onboarding and are now using the Pivot tubeless patch pump in real-world settings. - Modular Medical via AccessNewswire

Modular Medical explicitly frames Pivot as a pump for insulin-dependent adults still on multiple daily injections, a group it calls a large underserved market. CEO Jeb Besser described the moment as validating "our vision of creating a simpler, more accessible pump solution." A day later, the company also submitted software enhancements to the FDA for Pivot, aimed at more customization and UI improvements, saying it expects feedback in the coming weeks. That is the normal rhythm of a product moving from clearance into the real world.

CureStream's Reusable Insulin Pump with AI Approved takes a different angle on the same accessibility problem. The South Korean startup received Ministry of Food and Drug Safety approval on June 29 for ModuStream, a patch pump that separates a reusable main body from replaceable consumables. - Chosun

The sustainability pitch is the interesting part: consumables swap every 3.5 days while the main body is designed to last up to three years, and CureStream says it targets maintenance costs at half the level of existing products. Longer term, the company wants to pair ModuStream with its AI Pancreas algorithm, which it says can calculate insulin doses from CGM data alone, without meal or carb entry. It plans exploratory trials in 50 type 1 patients this year. Worth watching, though the AI piece is still early and unproven.

Sensors are getting smarter and, separately, we got fresh evidence on why access to them matters so much.

OTC Continuous Glucose Monitor Adds AI Features reports that Dexcom, following FDA approval of its over-the-counter Stelo for pediatric use, is adding AI coaching, meal recognition, and expanded lifestyle-pattern tracking, with a redesigned app due for U.S. release in July. - Medscape

Stelo is also headed to the UK, Australia, New Zealand, and South Korea later in 2026 through 2027. Two cautions belong in bold: Stelo is not designed for hypoglycemia alerts, so it is not a substitute for a therapeutic CGM if you need low alarms, and users should talk to a clinician before changing medication based on its output. As one expert told Medscape:

Here is the access reality that ties it together. A JAMA Network Open analysis from Montefiore Einstein found that among more than 2,000 patients prescribed CGMs, they were 13% less likely to require a hospital stay and 18% less likely to visit the ER, with meaningful improvements in blood sugar management. - Montefiore Einstein via PR Newswire

The companion coverage from Medical Republic adds detail: across 8,502 adults in 18 Montefiore primary care clinics over three years, CGM initiation was tied to a larger HbA1c drop at 12 months (-0.66 vs -0.17 percentage points), sustained for at least two years. - Medical Republic

The model shifts CGM prescribing from endocrinologists to primary care, training doctors, nurses, and patients alike. That matters because uptake was still modest at around 28%, and a quoted Australian GP noted the real bottleneck elsewhere is access to subsidized devices, not who does the prescribing.

On the algorithm side, a fully closed-loop system with insulin lispro plus pramlintide was presented at the ADA Scientific Sessions. In a randomized crossover trial, adding pramlintide produced time in range of 71.1% and 71.2% versus 72.1% for insulin plus placebo, so the study did not meet its noninferiority bar overall. - Healio

But in a subgroup of 10 adults whose control-arm time in range was under 70%, the pramlintide loop did better (67.9% vs 60.6%; P=.011) while using less total daily insulin. Researcher Doumat explained the rationale:

It is an early hint that the people who might gain most from a fully hands-off loop are those currently struggling, though larger trials are needed.

That is the through-line for this week: the loop is getting more modular, sensors are getting more context-aware, and the biggest lever on outcomes may still be simply getting these devices into more hands. Take care of yourselves, and we will see you next issue.